Validation and Characterization of Platelet-Rich Plasma in the Feline: A Prospective Analysis.

Nicole Chun,Valerie Wong,Jeff Curry,Sherman Canapp,Brittany Jean Carr

doi:10.3389/fvets.2020.00512

Nicole Chun, Valerie Wong + Show 3 more

Open Access

https://doi.org/10.3389/fvets.2020.00512

Copy DOI

Abstract

Objective: To quantitate key parameters of the platelet-rich plasma (PRP) product from a commercially available system1 in healthy, adult felines.Materials and methods: A prospective study was performed from January 2019 to April 2019. 11 adult, healthy cats were used to prospectively analyze a commercially available PRP system1. A whole blood sample and a PRP sample that was processed immediately following blood draw according to the manufacturer's protocol were collected from each cat. The mean whole blood and PRP product platelet, RBC, WBC, neutrophil, monocyte, and lymphocyte concentrations were determined. The mean PRP product values were compared to the mean whole blood baseline values using a paired t-test with significance established at p = 0.05.Results: Mean platelet concentration was significantly increased (p = 0.0155). Mean RBC concentration was significantly decreased (p < 0.0001). Mean neutrophil concentration was significantly decreased (p < 0.0001). There was no statistically significant difference in mean WBC, monocyte, and lymphocyte concentrations.Clinical Relevance: The analyzed PRP system increased platelet concentration, while significantly reducing the RBC and neutrophil concentrations. Further study is warranted to determine the clinical applications and efficacy of PRP in felines, and the ideal concentrations of and relationships between platelets, red blood cells, and leukocytes needed for therapeutic effect.

Highlights

Platelet-rich plasma (PRP) is an autologous blood concentrate of platelets
Numerous randomized controlled studies have looked at the efficacy of PRP for human knee osteoarthritis, showing that PRP can superiorly improve pain and function for up to 1 year when compared to other intra-articular therapies, including placebo, HA, saline and corticosteroids [7,8,9,10]
Mean PRP product platelet concentration (777.7 K/μL ± 561.1) was significantly increased by 151% (p = 0.0155), a 2.5-fold increase in platelets from baseline on average

Summary

Introduction

Platelet-rich plasma (PRP) is an autologous blood concentrate of platelets. Similar research in the canine is still in its infancy, but there are a growing number of reports demonstrating PRP’s ability to alter the joint environment and improve clinical function in dogs with OA. Many of these studies involve the combined use of PRP with stem cells, as platelets have been shown to recruit and differentiate stem cells, enhance their survival, and provide them with scaffolding [11,12,13,14,15,16]. Research shows better long-term results with a series of PRP injections, even in comparison to extracorporeal shockwave therapy (ESWT) and eccentric exercise [20]

Methods

Results

Conclusion